Showing results (141-150 of 159) with videos related to

Sort By:
Pageof 16
Blood|April 25, 2013
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationFarhad Ravandi, Mona Lisa Alattar, Michael R Grunwald, et al.
Blood|March 28, 2015
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R McCurdy, Jennifer A Kanakry, Margaret M Showel, et al.
Blood|October 7, 2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 studyEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Research Square|November 24, 2025
A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AMLTheodoros Karantanos, Nour Naji, Taha Ahmedna, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 21, 2014
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemiaYi-Bin Chen, Shuli Li, Andrew A Lane, et al.
Blood|June 2, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemiaEunice S Wang, Harry P Erba, Amer M Zeidan, et al.
Haematologica|April 15, 2021
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndromeMahesh Swaminathan, Hagop M Kantarjian, Mark Levis, et al.
The Lancet. Oncology|June 4, 2018
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trialJorge Cortes, Alexander E Perl, Hartmut Döhner, et al.
Transplantation and Cellular Therapy|November 7, 2025
Long-Term Follow-Up of the Baltimore Experience with Hematopoietic Cell Transplantation for Severe Aplastic Anemia Using Post-Transplantation CyclophosphamideAmy E DeZern, Marianna Zahurak, Tyler Cavin, et al.
The Lancet. Oncology|June 25, 2017
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 studyAlexander E Perl, Jessica K Altman, Jorge Cortes, et al.
Pageof 16